[HTML][HTML] Homologous and heterologous Covid-19 booster vaccinations
…, CM Posavad, JI Archer, S Crandon… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective, …
have received emergency use authorization in the United States are highly effective, …
[PDF][PDF] Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant
…, D Dobrzynski, RN Coler, JI Archer, S Crandon… - Cell Reports …, 2022 - cell.com
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost to …
[HTML][HTML] Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
infection wanes over time, requiring updated boosters. In a phase 2, open-label, …
[HTML][HTML] Cocoa consumption for 2 wk enhances insulin-mediated vasodilatation without improving blood pressure or insulin resistance in essential hypertension
…, G Hall, TL Kolodziej, RJ Karne, SK Crandon… - The American journal of …, 2008 - Elsevier
Background: Essential hypertension is characterized by reciprocal relations between
endothelial dysfunction and insulin resistance. Cocoa flavanols stimulate production of the …
endothelial dysfunction and insulin resistance. Cocoa flavanols stimulate production of the …
[HTML][HTML] Heterologous SARS-CoV-2 booster vaccinations–preliminary report
…, D Dobryzynski, CM Posavad, JI Archer, S Crandon… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Background: While Coronavirus disease 2019 (Covid-19) vaccines are highly effective,
breakthrough infections are occurring. Booster vaccinations have recently received emergency …
breakthrough infections are occurring. Booster vaccinations have recently received emergency …
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and …
Purpose: To determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic/pharmacodynamic
profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with …
profile of the Hsp90 inhibitor PF-04929113 (SNX-5422) in patients with …
[HTML][HTML] Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
…, D Szydlo, R PaulChoudhury, JI Archer, S Crandon… - npj Vaccines, 2023 - nature.com
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster
vaccines, we assessed the magnitude, breadth, and short-term durability of binding and …
vaccines, we assessed the magnitude, breadth, and short-term durability of binding and …
SARS-CoV-2 variant vaccine boosters trial: preliminary analyses
Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by
emerging variants including Omicron subvariants. This study evaluated safety and …
emerging variants including Omicron subvariants. This study evaluated safety and …
Oral glucosamine for 6 weeks at standard doses does not cause or worsen insulin resistance or endothelial dysfunction in lean or obese subjects
R Muniyappa, RJ Karne, G Hall, SK Crandon… - Diabetes, 2006 - Am Diabetes Assoc
Glucosamine is a popular nutritional supplement used to treat osteoarthritis. Intravenous
administration of glucosamine causes insulin resistance and endothelial dysfunction. However, …
administration of glucosamine causes insulin resistance and endothelial dysfunction. However, …
Immunogenicity of the BA. 1 and BA. 4/BA. 5 severe acute respiratory syndrome coronavirus 2 bivalent boosts: preliminary results from the COVAIL randomized …
…, M Makowski, MK Makhene, S Crandon… - Clinical Infectious …, 2023 - academic.oup.com
In a randomized clinical trial, we compare early neutralizing antibody responses after boosting
with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger …
with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger …
